Pseudomonas aeruginosa: Recent Advances in Vaccine Development
The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Pseudomonas aeruginosa is an important opportunistic human pathogen. Using its arsenal of virulence factors and its intrinsic ability to adapt to new environments, P. aeruginosa causes a range of complicated acute and chronic infections in immunocompromised individuals. Of particular importance are burn wound infections, ventilator-associated pneumonia, and chronic infections in people with cystic fibrosis. Antibiotic resistance has rendered many of these infections challenging to treat and novel therapeutic strategies are limited. Multiple clinical studies using well-characterised virulence factors as vaccine antigens over the last 50 years have fallen short, resulting in no effective vaccination being available for clinical use. Nonetheless, progress has been made in preclinical research, namely, in the realms of antigen discovery, adjuvant use, and novel delivery systems. Herein, we briefly review the scope of P. aeruginosa clinical infections and its major important virulence factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Foundational work on alginate conjugates and the OprF and OprI formulation IC43 shaped the field.”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [224]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142 · cited 1×
“The World Health Organisation (WHO) has prioritised Pseudomonas aeruginosa as one of the top three critical pathogens requiring urgent research into new treatments [1].”
BackgroundMechanisms of Antibiotic Resistance
Munita, J. M., & Arias, C. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.vmbf-0016-2015 · Cited by 2,782
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Pang, Z., Raudonis, R., Glick, B. R., Lin, T.-J., & Cheng, Z. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.11.013 · Cited by 2,306
Elborn, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00576-6 · Cited by 1,805
Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review
Mulani, M. S., Kamble, E. E., Kumkar, S. N., Tawre, M. S., & Pardesi, K. R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00539 · Cited by 1,644
Co-infections in people with COVID-19: a systematic review and meta-analysis.
Lansbury, L., Lim, B., Baskaran, V., & Lim, W. S. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.05.046 · Cited by 1,619
Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence
Moradali, M. F., Ghods, S., & Rehm, B. H. A. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00039 · Cited by 1,537
Pseudomonas aeruginosa: all roads lead to resistance
Breidenstein, E. B. M., de la Fuente-Núñez, C., & Hancock, R. E. W. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.04.005 · Cited by 1,286
Clinical and economic consequences of ventilator-associated pneumonia: A systematic review
Safdar, N., Dezfulian, C., Collard, H. R., & Saint, S. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000181731.53912.d9 · Cited by 1,086
Pseudomonas aeruginosa Biofilms
Thi, M. T. T., Wibowo, D., & Rehm, B. H. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228671 · Cited by 911
Mucosal vaccines — fortifying the frontiers
Lavelle, E. C., & Ward, R. W. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00583-2 · Cited by 752
Founou, R. C., Founou, L. L., & Essack, S. Y. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189621 · Cited by 710
Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors
Jurado-Martín, I., Sainz-Mejías, M., & McClean, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063128 · Cited by 698
Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis
Rossi, E., La Rosa, R., Bartell, J. A., Marvig, R. L., Haagensen, J. A. J., Sommer, L. M., Molin, S., & Johansen, H. K. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00477-5 · Cited by 525
Modern Subunit Vaccines: Development, Components, and Research Opportunities
Moyle, P. M., & Toth, I. (2013) · ChemMedChem · doi:10.1002/cmdc.201200487 · Cited by 464
Mechanisms of antibiotic resistance
Munita, J. M., & Arias, C. A. (2016) · Virulence Mechanisms of Bacterial Pathogens · doi:10.1128/9781555819286.ch17 · Cited by 421
Barken, K. B., Pamp, S. J., Yang, L., Gjermansen, M., Bertrand, J. J., Klausen, M., Givskov, M., Whitchurch, C. B., Engel, J. N., & Tolker‐Nielsen, T. (2008) · Environmental Microbiology · doi:10.1111/j.1462-2920.2008.01658.x · Cited by 418
Arancibia, F., Bauer, T. T., Ewig, S., Mensa, J., Gonzalez, J., Niederman, M. S., & Torres, A. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1849 · Cited by 401
Infections Caused by Resistant Gram‐Negative Bacteria: Epidemiology and Management
Kaye, K. S., & Pogue, J. M. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1636 · Cited by 383
Raman, G., Avendano, E. E., Chan, J., Merchant, S., & Puzniak, L. (2018) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-018-0370-9 · Cited by 269
Ellis, T. N., Leiman, S. A., & Kuehn, M. J. (2010) · Infection and Immunity · doi:10.1128/iai.00433-10 · Cited by 239
Innate immune responses to Pseudomonas aeruginosa infection
Lavoie, E. G., Wangdi, T., & Kazmierczak, B. I. (2011) · Microbes and Infection · doi:10.1016/j.micinf.2011.07.011 · Cited by 235
Innate immunity in cystic fibrosis lung disease
Hartl, D., Gaggar, A., Bruscia, E., Hector, A., Marcos, V., Jung, A., Greene, C., McElvaney, G., Mall, M., & Döring, G. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.07.003 · Cited by 230
Mall, M. A. (2008) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2007.0659 · Cited by 212
Restrepo, M. I., Babu, B. L., Reyes, L. F., Chalmers, J. D., Soni, N. J., Sibila, O., Faverio, P., Cilloniz, C., Rodriguez-Cintron, W., & Aliberti, S. (2018) · European Respiratory Journal · doi:10.1183/13993003.01190-2017 · Cited by 211
Outer membrane vesicle vaccines
Micoli, F., & MacLennan, C. A. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101433 · Cited by 204
Kollef, M. H., Chastre, J., Fagon, J.-Y., François, B., Niederman, M. S., Rello, J., Torres, A., Vincent, J.-L., Wunderink, R. G., Go, K. W., et al. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000510 · Cited by 203
Döring, G., Meisner, C., Stern, M., & for the Flagella Vaccine Trial Study Group (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702403104 · Cited by 186
Pseudomonas aeruginosa in premise plumbing of large buildings
Bédard, E., Prévost, M., & Déziel, E. (2016) · MicrobiologyOpen · doi:10.1002/mbo3.391 · Cited by 172
Immune Responses to Pseudomonas aeruginosa Biofilm Infections
Moser, C., Jensen, P. Ø., Thomsen, K., Kolpen, M., Rybtke, M., Lauland, A. S., Trøstrup, H., & Tolker-Nielsen, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.625597 · Cited by 170
Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report
Pressler, T., Bohmova, C., Conway, S., Dumcius, S., Hjelte, L., Høiby, N., Kollberg, H., Tümmler, B., & Vavrova, V. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60011-8 · Cited by 158
Solanki, V., Tiwari, M., & Tiwari, V. (2019) · Scientific Reports · doi:10.1038/s41598-019-41496-4 · Cited by 142
Pier, G. B., Saunders, J. M., Ames, P., Edwards, M. S., Auerbach, H. S., Goldfarb, J., Speert, D. P., & Hurwitch, S. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709243171303 · Cited by 140
Inflammation: A Double-Edged Sword in the Response to Pseudomonas aeruginosa Infection
Lin, C. K., & Kazmierczak, B. I. (2017) · Journal of Innate Immunity · doi:10.1159/000455857 · Cited by 132
Meluleni, G. J., Grout, M., Evans, D. J., & Pier, G. B. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.4.2029 · Cited by 129
Rau, M. H., Hansen, S. K., Johansen, H. K., Thomsen, L. E., Workman, C. T., Nielsen, K. F., Jelsbak, L., Høiby, N., Yang, L., & Molin, S. (2010) · Environmental Microbiology · doi:10.1111/j.1462-2920.2010.02211.x · Cited by 127
Th17-stimulating Protein Vaccines Confer Protection against Pseudomonas aeruginosa Pneumonia
Wu, W., Huang, J., Duan, B., Traficante, D. C., Hong, H., Risech, M., Lory, S., & Priebe, G. P. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201202-0182oc · Cited by 124
Innate antimicrobial immunity in the skin: A protective barrier against bacteria, viruses, and fungi
Coates, M., Blanchard, S., & MacLeod, A. S. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007353 · Cited by 121
Mutharia, L. M., & Hancock, R. E. W. (1983) · Infection and Immunity · doi:10.1128/iai.42.3.1027-1033.1983 · Cited by 120
Mucosal Vaccination via the Respiratory Tract
Hellfritzsch, M., & Scherließ, R. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11080375 · Cited by 118
Pitiriga, V. C., Kanellopoulos, P., Bakalis, I., Kampos, E., Sagris, I., Saroglou, G., & Tsakris, A. (2020) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-020-00851-1 · Cited by 114
Understanding Pseudomonas aeruginosa–Host Interactions: The Ongoing Quest for an Efficacious Vaccine
Sainz-Mejías, M., Jurado‐Martín, I., & McClean, S. (2020) · Cells · doi:10.3390/cells9122617 · Cited by 104
Lang, A. B., Rüdeberg, A., Schöni, M. H., Que, J. U., Fürer, E., & Schaad, U. B. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000129688.50588.ac · Cited by 101
Bacterial Ghosts-Based Vaccine and Drug Delivery Systems
Chen, H., Ji, H., Kong, X., Lei, P., Yang, Q., Wu, W., Jin, L., & Sun, D. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111892 · Cited by 95
Westritschnig, K., Hochreiter, R., Wallner, G., Firbas, C., Schwameis, M., & Jilma, B. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26565 · Cited by 93
Johansen, H. K., Nørregaard, L. L., Gøtzsche, P. C., et al. (2004) · Pediatric Pulmonology · doi:10.1002/ppul.10457 · Cited by 87
Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine
Pier, G. B., DesJardin, D., Grout, M., Garner, C., Bennett, S. E., Pekoe, G., Fuller, S. A., Thornton, M. O., Harkonen, W. S., & Miller, H. C. (1994) · Infection and Immunity · doi:10.1128/iai.62.9.3972-3979.1994 · Cited by 84
Early Infections Complicating the Care of Combat Casualties from Iraq and Afghanistan
Weintrob, A., Murray, C. K., Xu, J., Krauss, M. R., Bradley, W. P. L., Warkentien, T. E., Lloyd, B. A., & Tribble, D. R. (2018) · Surgical Infections · doi:10.1089/sur.2017.240 · Cited by 84
McIsaac, S. M., Stadnyk, A. W., & Lin, T.-J. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0811410 · Cited by 83
Pseudomonas aeruginosa polymicrobial interactions during lung infection
Bisht, K., Baishya, J., & Wakeman, C. A. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.01.014 · Cited by 82
A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients
Rello, J., Krenn, C.-G., Locker, G., Pilger, E., Madl, C., Balica, L., Dugernier, T., Laterre, P.-F., Spapen, H., Depuydt, P., et al. (2017) · Critical Care · doi:10.1186/s13054-017-1601-9 · Cited by 80
Mansouri, E., Gabelsberger, J., Knapp, B., Hundt, E., Lenz, U., Hungerer, K., Gilleland, H. E., Staczek, J., Domdey, H., & Specht, B.-U. V. (1999) · Infection and Immunity · doi:10.1128/iai.67.3.1461-1470.1999 · Cited by 78
Rashid, M. I., Naz, A., Ali, A., & Andleeb, S. (2017) · Genomics · doi:10.1016/j.ygeno.2017.05.001 · Cited by 75
Solleti, V. S. T., Alhariri, M., Halwani, M., & Omri, A. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku452 · Cited by 69
Ehsan, Z., & Clancy, J. P. (2015) · Future Microbiology · doi:10.2217/fmb.15.117 · Cited by 67
Rodgers, A. M., McCrudden, M., Vicente-Perez, E. M., Dubois, A. V., Ingram, R. J., Larrañeta, E., Kissenpfennig, A., & Donnelly, R. F. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.07.049 · Cited by 62
Self-citationMauch, R. M., Jensen, P. Ø., Moser, C. E., Levy, C. E., & Høiby, N. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.08.012 · Cited by 61
Baidya, S., Sharma, S., Mishra, S. K., Kattel, H. P., Parajuli, K., & Sherchand, J. B. (2021) · BioMed Research International · doi:10.1155/2021/8817700 · Cited by 61
Genome-Based Approach Delivers Vaccine Candidates Against Pseudomonas aeruginosa
Bianconi, I., Alcalá-Franco, B., Scarselli, M., Dalsass, M., Buccato, S., Colaprico, A., Marchi, S., Masignani, V., & Bragonzi, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03021 · Cited by 56
Larbig, M., Mansouri, E., Freihorst, J., Tümmler, B., Köhler, G., Domdey, H., Knapp, B., Hungerer, K. D., Hundt, E., Gabelsberger, J., et al. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00550-8 · Cited by 56
Immunological considerations in the development of Pseudomonas aeruginosa vaccines
Baker, S. M., McLachlan, J. B., & Morici, L. A. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1650999 · Cited by 56
Kwok, W. C., Ho, J., Tam, T. C. C., Ip, M., & Lam, D. C. L. (2021) · Respiratory Research · doi:10.1186/s12931-021-01729-5 · Cited by 51
Inflammatory markers in cystic fibrosis patients with transmissiblePseudomonas aeruginosa
Jones, A. M., Martin, L., Bright-Thomas, R. J., Dodd, M. E., McDowell, A., Moffitt, K. L., Elborn, J. S., & Webb, A. K. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00004503 · Cited by 47
Molecular characterization of the outer membrane of Pseudomonas aeruginosa
López, C. A., Zgurskaya, H. I., & Gnanakaran, S. (2019) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2019.183151 · Cited by 47
Baumann, U., Göcke, K., Gewecke, B., Freihorst, J., & von Specht, B. U. (2007) · Respiratory Research · doi:10.1186/1465-9921-8-57 · Cited by 45
Pseudomonas aeruginosa in cystic fibrosis: A chronic cheater
Waters, C. M., & Goldberg, J. B. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902734116 · Cited by 43
Göcke, K., Baumann, U., Hagemann, H., Gabelsberger, J., Hahn, H., Freihorst, J., & von Specht, B. U. (2003) · FEMS Immunology & Medical Microbiology · doi:10.1016/s0928-8244(03)00094-4 · Cited by 41
Heurtault, B., Gentine, P., Thomann, J., Baehr, C., Frisch, B., & Pons, F. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9724-y · Cited by 38
New markers for sepsis caused by Pseudomonas aeruginosa during burn infection
Elmassry, M. M., Mudaliar, N. S., Colmer-Hamood, J. A., San Francisco, M. J., Griswold, J. A., Dissanaike, S., & Hamood, A. N. (2020) · Metabolomics · doi:10.1007/s11306-020-01658-2 · Cited by 37
Ma, C., Ma, X., Jiang, B.-G., Pan, H., Liao, X., Zhang, L., Li, W., Luo, Y., Shen, Z., Cheng, X., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00752-8 · Cited by 35
Das, S., Howlader, D. R., Zheng, Q., Ratnakaram, S. S. K., Whittier, S. K., Lu, T., Keith, J. D., Picking, W. D., Birket, S. E., & Picking, W. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583008 · Cited by 33
Zanjani, L. S., Shapouri, R., Dezfulian, M., Mahdavi, M., & Ardestani, M. S. (2019) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-019-2669-y · Cited by 28
Sorichter, S., Baumann, U., Baumgart, A., Walterspacher, S., & Specht, B.-U. V. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.010 · Cited by 28
Fan, Y., Mu, Y., Lu, L., Tian, Y., Yuan, F., Zhou, B., Yu, C., Wang, Z., Li, X., Lei, S., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.01.055 · Cited by 26
Ortiz, J. A., Llanos-González, E., Toledano, V., del Campo, R., Cubillos‐Zapata, C., Lozano‐Rodríguez, R., Ismail, A., Prados, C., Gómez‐Campelo, P., Aguirre, L. A., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.11.002 · Cited by 25
Mayeux, G., Gayet, L., Liguori, L., Odier, M., Martin, D. K., Cortès, S., Schaack, B., & Lenormand, J. (2021) · Life Science Alliance · doi:10.26508/lsa.202000958 · Cited by 24
Li, P., Wang, X., Sun, X., Cimino, J. L., Guan, Z., & Sun, W. (2021) · Infection and Immunity · doi:10.1128/iai.00396-21 · Cited by 24
Aguilera-Herce, J., García‐Quintanilla, M., Romero-Flores, R., McConnell, M. J., & Ramos‐Morales, F. (2019) · mSphere · doi:10.1128/msphere.00116-19 · Cited by 24
Li, P., Wang, X., Sun, X., Guan, Z., & Sun, W. (2021) · mSphere · doi:10.1128/msphere.00699-21 · Cited by 22
Baker, S. M., Pociask, D. A., Clements, J. D., McLachlan, J. B., & Morici, L. A. (2019) · Vaccine · doi:10.1016/j.vaccine.2018.12.053 · Cited by 19
Gonzaga, Z. J., Zhang, J., & Rehm, B. H. A. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00434 · Cited by 19
Chen, Y., Yang, F., Yang, J., Hou, Y., He, L., Hu, H., & Lv, F. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b18164 · Cited by 17
Jing, H., Zhang, X., Zou, J., Yuan, Y., Chen, Z., Liu, D., Wu, W., Yang, F., Lu, D., Zou, Q., et al. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.05.057 · Cited by 12
Lectin activity of Pseudomonas aeruginosa vaccine candidates PSE17-1, PSE41-5 and PSE54
Day, C. J., Hartley‐Tassell, L. E., Seib, K. L., Tiralongo, J., Bovin, N. V., Savino, S., Masignani, V., & Jennings, M. P. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.092 · Cited by 11
Searching for simple rules in Pseudomonas aeruginosa biofilm formation
Deveaux, W., & Selvarajoo, K. (2019) · BMC Research Notes · doi:10.1186/s13104-019-4795-x
Pseudomonas aeruginosa bacteraemia in burns patients: Risk factors and outcomes
Mahar, P. D., Padiglione, A. A., Cleland, H. J., Paul, E. M., Hinrichs, M., & Wasiak, J. (2010) · Burns · doi:10.1016/j.burns.2010.05.009
Bronchoscope-Related “Superbug” Infections
Mehta, A. C., & Muscarella, L. F. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.08.003
Kaier, K., Heister, T., Götting, T., Wolkewitz, M., & Mutters, N. T. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4660-5
Vaccination for pseudomonas aeruginosa
Alexander, J. W., & Fisher, M. W. (1970) · The American Journal of Surgery · doi:10.1016/s0002-9610(70)80019-8
Pseudomonas aeruginosa Vaccine in Cancer Patients
Young, L. S., MEYER, R. D., & ARMSTRONG, D. (1973) · Annals of Internal Medicine · doi:10.7326/0003-4819-79-4-518
Pennington, J. E. (1974) · The Journal of Infectious Diseases · doi:10.1093/infdis/130.supplement.s159
Use of a Pseudomonas aeruginosa vaccine in patients with acute leukemia and cystic fibrosis
Pennington, J. E., Reynolds, H. Y., Wood, R. E., Robinson, R. A., & Levine, A. S. (1975) · The American Journal of Medicine · doi:10.1016/0002-9343(75)90498-2
A newPseudomonasvaccine: Preliminary trial on human volunteers
Jones, R. J., Roe, E. A., Lowbury, E. J. L., Miler, J. J., & Spilsbury, J. F. (1976) · Journal of Hygiene · doi:10.1017/s0022172400055364
Roe, E. A., & Jones, R. J. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.supplement_5.s922
Langford, D. T., & Hiller, J. (1984) · Archives of Disease in Childhood · doi:10.1136/adc.59.12.1131
Cryz, S. J., Fürer, E., Cross, A. S., Wegmann, A., Germanier, R., & SADOFF, J. C. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113062
Cryz, S. J., SADOFF, J. C., & Fürer, E. (1988) · Infection and Immunity · doi:10.1128/iai.56.7.1829-1830.1988
Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis
Schaad, U. B., Wedgwood, J., Rüdeberg, A., Lang, A. B., Que, J. U., Fürer, E., & Cryz, S. J. (1991) · The Lancet · doi:10.1016/0140-6736(91)92103-9
Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients
Döring, G. (2010) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2010.08.010
Cripps, A. W., Peek, K., Dunkley, M. L., Vento, K., Marjason, J. K., McIntyre, M. E., Sizer, P., Croft, D., & Sedlak-Weinstein, L. (2006) · Infection and Immunity · doi:10.1128/iai.74.2.968-974.2006
Mansouri, E., Blome-Eberwein, S. A., Gabelsberger, J., Germann, G., & Specht, B.-U. (2003) · FEMS Immunology & Medical Microbiology · doi:10.1016/s0928-8244(03)00072-5
Adlbrecht, C., Wurm, R., Depuydt, P. O., Spapen, H. D., Lorente, J. A., Staudinger, T., Créteur, J., Zauner, C., Meier‐Hellmann, A., Eller, P., et al. (2020) · Critical Care · doi:10.1186/s13054-020-2792-z
Zuercher, A. W., Imboden, M. A., Jampen, S., Bosse, D., Ulrich, M., Chtioui, H., Lauterburg, B. H., & Lang, A. B. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02925.x
von Specht, B. U., Knapp, B., Muth, G., Bröker, M., Hungerer, K. D., Diehl, K.-D., Massarrat, K., Seemann, A., & Domdey, H. (1995) · Infection and Immunity · doi:10.1128/iai.63.5.1855-1862.1995
von Specht, B. U., Gabelsberger, J., Knapp, B., Hundt, E., Schmidt-Pilger, H., Bauernsachs, S., Lenz, U., & Domdey, H. (2000) · Journal of Biotechnology · doi:10.1016/s0168-1656(00)00311-4
Complement activation by Pseudomonas aeruginosa biofilms
Jensen, E. T., Kharazmi, A., Garred, P., Kronborg, G., Fomsgaard, A., Mollnes, T. E., & Høiby, N. (1993) · Microbial Pathogenesis · doi:10.1006/mpat.1993.1087
Meynet, E., Laurin, D., Lenormand, J., Camara, B., Toussaint, B., & Gouëllec, A. L. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.040
OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa
Ding, B., Specht, B.-U. V., & Li, Y. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.04.028
Editorial: Reverse Vaccinology
Moxon, R. E., Reche, P. A., & Rappuoli, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02776
Gbian, D. L., & Omri, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040577
Bumann, D., Behre, C., Behre, K., Herz, S., Gewecke, B., Gessner, J. E., von Specht, B. U., & Baumann, U. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.080
Zhang, M., Sun, C., Gu, J., Yan, X., Wang, B., Cui, Z., Sun, X., Tong, C., Feng, X., Lei, L., et al. (2015) · Microbiology and Immunology · doi:10.1111/1348-0421.12291
Sheweita, S. A., Amara, A. A. A. F., Gamal, H., Ghazy, A. A., Hussein, A., & Bahey-El-Din, M. (2022) · Vaccines · doi:10.3390/vaccines10060910
Cui, Z., Han, D., Sun, X., Zhang, M., Feng, X., Sun, C., Gu, J., Tong, C., Lei, L., & Han, W. (2014) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-014-6147-z
Howlader, D. R., Das, S., Lu, T., Hu, G., Varisco, D. J., Dietz, Z. K., Walton, S. P., Ratnakaram, S. S. K., Gardner, F. M., Ernst, R. K., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.706157
Research works printed but not linked: 8
- Olejnickova, 2014, Catheter-related infections caused by Pseudomonas aeruginosa: Virulence factors involved and their relationships, Pathog. Dis., 72, 87
- Costas, 2016, Specific immune response against Pseudomonas aeruginosa and haemophilus influenzae in severe COPD, Eur. Respir. J., 48, OA1790
- Crowe, 1991, The First Clinical Trial of Immuno’s Experimental Pseudomonas aeruginosa Flagellar Vaccines, Pseudomonas Aeruginosa Hum. Dis., 44, 143
- Pfeiffer, 1995, Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals, Am. J. Respir. Crit. Care Med., 151, 983
- Cripps, 1997, Vaccine strategies against Pseudomonas aeruginosa infection in the lung, Behring Inst. Mitt., 98, 262
- Kiyono, H., and Pascual, D.W. (2020). Mucosal Vaccines, Academic Press. [2nd ed.].
- Najafzadeh, 2021, Immunological Properties of Exotoxin A Toxoid—Detoxified Lipopolysaccharide—Gold Nanoparticles Conjugate Against Pseudomonas aeruginosa Infection, Iran. J. Immunol., 18, 292
- Azimi, 2021, Immunization against Pseudomonas aeruginosa using Alg-PLGA nano-vaccine, Iran. J. Basic Med Sci., 24, 476
Cited by
Elfadadny, A., Ragab, R. F., AlHarbi, M., Badshah, F., Ibáñez-Arancibia, E., Farag, A., Hendawy, A. O., De los Ríos-Escalante, P. R., Aboubakr, M., Zakai, S. A., et al. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1374466 · Cited by 340
Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics
Wood, S. J., Kuzel, T. M., & Shafikhani, S. H. (2023) · Cells · doi:10.3390/cells12010199 · Cited by 254
Elbehiry, A., Marzouk, E., Edrees, H. M., Ibrahem, M., Alzahrani, S., Anagreyyah, S., Abualola, H., Alghamdi, A., Alzahrani, A., Jaber, M., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14010109 · Cited by 34
Badten, A. J., & Torres, A. G. (2024) · Vaccines · doi:10.3390/vaccines12030313 · Cited by 8
Metadata
- Authors
- Killough, M., Rodgers, A., & Ingram, R.
- Venue
- Vaccines
- Publisher
- MDPI AG
- Published
- 2022-07-08
- Volume
- 10
- Issue
- 7
- Pages
- 1100
- ISSN
- 2076-393X
- Cited by
- 93
- References
- 115
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.